Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: Neocortical Epilepsies - Do They Progress? [NA]
A completed clinical trial investigating progression in neocortical epilepsies; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-15Clinical Trial Update: Hippocampal and Thalamic DBS for Bilateral Temporal Lobe Epilepsy [Phase 4]
Phase 4 clinical trial update evaluating hippocampal and thalamic deep brain stimulation for bilateral temporal lobe epilepsy.
-
FDA approval · 2019-11-06FDA Approved: DIAZEPAM — Supplemental Application (Natco Pharma USA LLC)
The FDA approved a supplemental application for Diazepam from Natco Pharma USA LLC, granting approval of generic diazepam under ANDA210363.
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: Effect of GABA on ADHD and Seizures in Children With Epilepsy. [Phase 4]
Phase 4 clinical trial updating the effect of GABA on ADHD and seizures in children with epilepsy; currently recruiting.
-
FDA approval · 2019-10-29FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for lamotrigine submitted by Zydus Pharmaceuticals USA Inc. The exact changes covered by the supplem…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-10-29FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for lamotrigine from Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2019-10-23FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA (levetiracetam) submitted by UCB, Inc. The approval updates the product labeling and may …
-
FDA label_change · 2019-10-23FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA (levetiracetam) submitted by UCB, Inc., likely updating the product labeling. The act…
-
FDA approval · 2019-10-23FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approves a supplemental application for KEPPRA XR (extended-release levetiracetam) from UCB, Inc., adding/confirming approval of the ext…
-
FDA approval · 2019-10-21FDA Approved: FOSPHENYTOIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for fosphenytoin sodium from Amneal Pharmaceuticals LLC.
-
FDA approval · 2019-10-18FDA Approved: DIVALPROEX SODIUM — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' divalproex sodium as a generic product under Original Application (ANDA 209286).
-
CLINICAL_TRIALS trial_result · 2019-09-26Clinical Trial Update: Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy [Phase 4]
Phase 4 clinical trial update evaluating ivermectin treatment in persons with onchocerciasis-associated epilepsy has completed.
-
FDA approval · 2019-09-25FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for Lamictal (lamotrigine) submitted by GlaxoSmithKline LLC. The approval pertains to a suppleme…
-
FDA label_change · 2019-09-25FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal ODT (lamotrigine) submitted by GlaxoSmithKline LLC, updating the product labeling.
-
FDA approval · 2019-09-12FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for Sabril (vigabatrin) from Lundbeck Pharmaceuticals LLC, typically resulting in updates to lab…
-
FDA approval · 2019-09-12FDA Approved: VIGABATRIN — Supplemental Application (Dr. Reddys Laboratories Inc.,)
FDA approved a supplemental application for Vigabatrin submitted by Dr. Reddy's Laboratories Inc., enabling continued availability of the ge…
-
CLINICAL_TRIALS trial_result · 2019-09-12Clinical Trial Update: Anxiety and Depression in Epilepsy: A Pilot Treatment Study [Phase 4]
A Phase 4 pilot study on anxiety and depression in epilepsy was withdrawn.
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging [Phase 4]
A Phase 4 pilot trial evaluating dexmedetomidine-propofol for sedation in children undergoing MRI; results completed and posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-08-20Clinical Trial Update: Transcranial Magnetic Stimulation for Epilepsy [NA]
Clinical trial update indicates termination for a transcranial magnetic stimulation study in epilepsy; results posted in 2019.
-
FDA approval · 2019-08-14FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for LAMICTAL ODT (lamotrigine) from GlaxoSmithKline LLC.
-
FDA approval · 2019-08-14FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approves a supplemental application for LAMICTAL (lamotrigine) submitted by GlaxoSmithKline LLC.
-
FDA approval · 2019-08-09FDA Approved: LEVETIRACETAM — Original Application (Micro Labs Limited)
FDA approved a generic formulation of levetiracetam from Micro Labs Limited under ANDA211954.
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome [Phase 3]
A Phase 3 trial evaluating cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome has completed with results posted in 2…
-
FDA approval · 2019-07-31FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for SABRIL (vigabatrin) submitted by Lundbeck Pharmaceuticals LLC.
-
FDA label_change · 2019-07-31FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approves a supplemental application for Sabril (vigabatrin) by Lundbeck Pharmaceuticals LLC, resulting in changes to the product's label…